Immunostimulatory activity of exopolysaccharides from probiotic Lactobacillus casei WXD030 strain as a novel adjuvant in vitro and in vivo

Exopolysaccharides act as mediators of cross-talk between probiotics and the host. Here, we found that EPS derived from probiotic Lactobacillus casei WXD030 strain (L-EPS) could modulate immune responses in vitro and in vivo. L-EPS could significantly enhance the proliferation and phagocytic activit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lei Xiu, Haochi Zhang, Zhongpeng Hu, Yanchen Liang, Shuai Guo, Ming Yang, Ruiping Du, Xiao Wang
Formato: article
Lenguaje:EN
Publicado: Taylor & Francis Group 2018
Materias:
Acceso en línea:https://doaj.org/article/7c3d42cc2c04429bac7b4c46a1104ec4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Exopolysaccharides act as mediators of cross-talk between probiotics and the host. Here, we found that EPS derived from probiotic Lactobacillus casei WXD030 strain (L-EPS) could modulate immune responses in vitro and in vivo. L-EPS could significantly enhance the proliferation and phagocytic activity as well as induce the production of NO, TNF-α, IL-1β and IL-6 in RAW264.7 cells. Furthermore, L-EPS could induce the maturation of BMDCs. In addition, L-EPS could largely increase the titres of OVA-specific antibodies and markedly enhanced T cell proliferation. Notably, L-EPS also increased expression of IL-4 and INF-γ expression in CD4+T cells. Consistently, when used as an adjuvant in vivo with the foot-and-mouth disease vaccine, L-EPS largely enhanced the FMDV-specific antibody production. Collectively, these results suggested that L-EPS derived from probiotic L. casei strain had adjuvant activity, which may be a safe and efficacious adjuvant candidate suitable for a wide spectrum of prophylactic and therapeutic vaccines.